Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian drug user fees for product applications become effective Sept. 1.

This article was originally published in The Tan Sheet

Executive Summary

CANADIAN DRUG USER FEE SYSTEM WILL BE EFFECTIVE SEPT. 1 for premarket approval submission evaluations. Slated for publication in Part II of the Canada Gazette the week of Aug. 28, the "cost recovery" final regulation outlines fees that must be paid by prescription and nonprescription drug manufacturers for the review of drug-related submissions by the Canadian Health Protection Branch (HPB). The submissions evaluation fees are expected to bring in $25 mil. a year for HPB.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel